Genky DrugStores Co., Ltd. (JP:9267)
:9267
Top Page
Genky DrugStores Co., Ltd.
(9267)
Select Model
Select Model
Rating:73Outperform
Price Target:
¥4,640.00
▼(-6.45% Downside)
Action:ReiteratedDate:10/31/25
Genky DrugStores Co., Ltd. shows strong financial performance with consistent revenue growth and profitability, which is the most significant factor in the overall score. The technical analysis indicates a bullish trend, supporting the positive outlook. However, the valuation is only fair, with a low dividend yield, which slightly tempers the overall score.
Positive Factors
Consistent Revenue Growth
Multi-year revenue expansion indicates persistent demand for daily-consumable categories. A broad mix of OTC, H&B, household and food supports frequent customer visits and basket growth, underpinning durable top-line momentum beyond short-term cycles.
Negative Factors
Negative Free Cash Flow
Negative FCF after capex suggests cash generation doesn't fully cover investments, constraining ability to self-fund growth, pay higher dividends, or build buffers. If persistent, it may force higher borrowing or slower strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Multi-year revenue expansion indicates persistent demand for daily-consumable categories. A broad mix of OTC, H&B, household and food supports frequent customer visits and basket growth, underpinning durable top-line momentum beyond short-term cycles.
Read all positive factors
Genky DrugStores Co., Ltd. (9267) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥129.69B
Dividend Yield0.25%
Average Volume (3M)62.69K
Price to Earnings (P/E)19.0
Beta (1Y)0.43
Revenue Growth9.97%
EPS Growth16.27%
CountryJP
Employees1,661
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding31,031,569
10 Day Avg. Volume60,060
30 Day Avg. Volume62,690
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)2.17
Price to Sales (P/S)0.58
P/FCF Ratio-46.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genky DrugStores Co., Ltd. Business Overview & Revenue Model
Company Description
Genky DrugStores Co., Ltd. operates a chain of drug stores. The company was founded in 1988 and is headquartered in Sakai, Japan....
How the Company Makes Money
Genky DrugStores generates revenue primarily through retail sales made at its drugstore locations. Its key revenue streams come from (1) OTC drugs and quasi-drugs (e.g., common medicines and related regulated products), (2) health & beauty items s...
Genky DrugStores Co., Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 200.79B | 184.86B | 169.06B | 154.64B | 142.38B |
| Gross Profit | 35.09B | 32.53B | 29.90B | 26.68B | 26.55B |
| EBITDA | 15.95B | 14.58B | 11.66B | 10.27B | 10.35B |
| Net Income | 7.07B | 6.32B | 4.76B | 4.42B | 4.83B |
Balance Sheet | |||||
| Total Assets | 128.27B | 114.84B | 106.92B | 97.64B | 91.28B |
| Cash, Cash Equivalents and Short-Term Investments | 6.22B | 5.90B | 5.33B | 5.44B | 7.91B |
| Total Debt | 34.37B | 30.65B | 32.35B | 30.96B | 28.56B |
| Total Liabilities | 74.84B | 68.15B | 66.23B | 61.40B | 59.11B |
| Stockholders Equity | 53.43B | 46.68B | 40.68B | 36.23B | 32.17B |
Cash Flow | |||||
| Free Cash Flow | -2.50B | 2.98B | -1.12B | -4.39B | 3.26B |
| Operating Cash Flow | 12.60B | 13.26B | 8.77B | 6.08B | 12.08B |
| Investing Cash Flow | -15.62B | -10.63B | -9.74B | -10.59B | -8.83B |
| Financing Cash Flow | 3.35B | -2.06B | 854.00M | 2.04B | -1.95B |
Genky DrugStores Co., Ltd. Technical Analysis
Neutral
4960.00
Price Trends
4191.50
Positive
4551.73
Negative
4538.73
Negative
Market Momentum
-15.14
Negative
59.03
Neutral
94.40
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9267, the sentiment is Neutral. The current price of 4960 is above the 20-day moving average (MA) of 3959.00, above the 50-day MA of 4191.50, and above the 200-day MA of 4538.73, indicating a neutral trend. The MACD of -15.14 indicates Negative momentum. The RSI at 59.03 is Neutral, neither overbought nor oversold. The STOCH value of 94.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:9267.
Genky DrugStores Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥684.54B | 23.29 | 15.71% | 0.96% | 21.81% | 67.76% | |
73 Outperform | ¥129.69B | 19.05 | ― | 0.25% | 9.97% | 16.27% | |
69 Neutral | ¥465.59B | 14.05 | 11.37% | 3.04% | 6.32% | 8.19% | |
67 Neutral | ¥1.12T | 25.31 | ― | 1.72% | ― | ― | |
67 Neutral | ¥373.38B | 20.79 | ― | 0.41% | 15.81% | 27.05% | |
60 Neutral | ¥543.51B | 22.79 | ― | 0.93% | 3.73% | 18.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:9267
Genky DrugStores Co., Ltd.
4,220.00
1,505.28
55.45%
JP:9989
Sundrug Co
3,982.00
-179.24
-4.31%
JP:7649
Sugi Holdings Co
3,632.00
825.85
29.43%
JP:3391
TSURUHA Holdings
2,489.50
560.75
29.07%
JP:3349
COSMOS Pharmaceutical Corporation
6,828.00
-856.37
-11.14%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,905.00
965.88
32.86%
Genky DrugStores Co., Ltd. Corporate Events
Genky DrugStores Extends Sales Growth as Store Network Reaches 510
Mar 31, 2026
Genky DrugStores reported solid year-on-year sales growth for March in both all stores and existing stores, supported by rising customer traffic despite slightly weaker spending per customer. The company continues to standardize its network, openi...
Genky DrugStores Extends Store Network as Same-Store Sales Level Off in February
Feb 27, 2026
Genky DrugStores reported continued top-line growth in February for all stores, with net sales up year on year and total store count rising to 503 as it opened three new standardized regular stores and recorded no closures. Existing stores saw fla...
Genky DrugStores Sustains Growth as It Accelerates Store Expansion and Capital Investment
Jan 27, 2026
Genky DrugStores reported continued top-line and profit growth through FY2025 and into FY2026, supported by steady same-store sales increases, disciplined cost control, and an expanding store network. The company plans to accelerate new store open...
Genky DrugStores Delivers Strong First-Half Profit Growth and Confirms Full-Year Outlook
Jan 27, 2026
Genky DrugStores reported solid results for the six months ended December 20, 2025, with net sales rising 10.6% year on year to ¥109.3 billion and net income attributable to owners of the parent increasing 23.0% to ¥4.0 billion, reflecti...
Genky DrugStores Tops 500 Stores as January Sales Rise on Network Expansion
Jan 27, 2026
Genky DrugStores reported that in January of the fiscal year ending June 2026, total net sales across all stores rose 5.7% year on year, while existing-store sales dipped 1.4%, reflecting flat customer traffic and a decline in spending per custome...
Genky DrugStores Lifts Profit Outlook While Moderating New Store Openings Amid Rising Costs
Jan 22, 2026
Genky DrugStores has raised its consolidated earnings forecasts for both the first half and full fiscal year ending June 2026, projecting higher operating, ordinary and net income despite largely unchanged net sales. The upgrade reflects better-th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.